BR0006088A - Derivados de proteìna c - Google Patents

Derivados de proteìna c

Info

Publication number
BR0006088A
BR0006088A BR0006088-7A BR0006088A BR0006088A BR 0006088 A BR0006088 A BR 0006088A BR 0006088 A BR0006088 A BR 0006088A BR 0006088 A BR0006088 A BR 0006088A
Authority
BR
Brazil
Prior art keywords
protein
derivatives
polypeptides
human
protein derivatives
Prior art date
Application number
BR0006088-7A
Other languages
English (en)
Portuguese (pt)
Inventor
Bruce Edward Gerlitz
Bryan Edward Jones
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BR0006088A publication Critical patent/BR0006088A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6464—Protein C (3.4.21.69)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
BR0006088-7A 1999-04-30 2000-04-13 Derivados de proteìna c BR0006088A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13180199P 1999-04-30 1999-04-30
PCT/US2000/008722 WO2000066754A1 (en) 1999-04-30 2000-04-13 Protein c derivatives

Publications (1)

Publication Number Publication Date
BR0006088A true BR0006088A (pt) 2001-03-20

Family

ID=22451086

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0006088-7A BR0006088A (pt) 1999-04-30 2000-04-13 Derivados de proteìna c

Country Status (11)

Country Link
EP (1) EP1090130A1 (es)
JP (1) JP2002542832A (es)
KR (1) KR20010053345A (es)
AR (1) AR029627A1 (es)
AU (1) AU4188500A (es)
BR (1) BR0006088A (es)
CA (1) CA2338799A1 (es)
HU (1) HUP0102444A3 (es)
IL (1) IL140326A0 (es)
PE (1) PE20010066A1 (es)
WO (1) WO2000066754A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000030677A1 (en) * 1998-11-20 2000-06-02 Eli Lilly And Company Method of treating viral hemorrhagic fever
US6998122B1 (en) 1999-04-30 2006-02-14 Eli Lilly And Company Protein C derivatives
ES2234807T3 (es) 2000-02-02 2005-07-01 Eli Lilly And Company Derivados de proteina c.
US6630138B2 (en) 2000-02-11 2003-10-07 Eli Lilly And Company Protein C derivatives
JPWO2002028416A1 (ja) * 2000-09-30 2004-02-12 持田製薬株式会社 溶血性貧血の予防・治療剤
US6933367B2 (en) 2000-10-18 2005-08-23 Maxygen Aps Protein C or activated protein C-like molecules
MXPA03003388A (es) * 2000-10-18 2005-03-07 Maxygen Aps Moleculas de proteina c o similares a las de proteina c activadas.
WO2006044294A2 (en) * 2004-10-14 2006-04-27 Eli Lilly And Company Human protein c analogs
WO2023171719A1 (ja) * 2022-03-08 2023-09-14 学校法人自治医科大学 活性化プロテインｃ配列

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0506821B1 (en) * 1989-12-29 1998-02-04 Zymogenetics, Inc. Hybrid protein c
US5358932A (en) * 1989-12-29 1994-10-25 Zymogenetics, Inc. Hybrid protein C
AU730133B2 (en) * 1996-11-08 2001-02-22 Oklahoma Medical Research Foundation Modified protein C and methods of use thereof

Also Published As

Publication number Publication date
HUP0102444A3 (en) 2003-09-29
AU4188500A (en) 2000-11-17
WO2000066754A1 (en) 2000-11-09
IL140326A0 (en) 2002-02-10
KR20010053345A (ko) 2001-06-25
HUP0102444A2 (hu) 2001-10-28
PE20010066A1 (es) 2001-02-02
AR029627A1 (es) 2003-07-10
JP2002542832A (ja) 2002-12-17
CA2338799A1 (en) 2000-11-09
EP1090130A1 (en) 2001-04-11

Similar Documents

Publication Publication Date Title
BR9611210A (pt) Composições e processos para tratamento de condições ósseas deficitárias
BR9811825A (pt) Uso de lactobacillus para redução do nìvel de fibrinogênio no sangue
DK0910647T3 (da) Human DNase i hyperaktive varianter
PT1196444E (pt) Conjugados de exendina-4 e seus usos medicos
DE60143292D1 (de) Varianten des menschlichen Koagulationsfaktors VII
BR0207006A (pt) Composição farmacêutica, kit, uso de uma preparação de um fator vii ou polipeptìdeo relacionado ao fator vii em combinação com uma preparação de um fator ix ou polipeptìdeo relacionado ao fator ix, uso de uma composição, método para tratar de episódios de hemorragia em um paciente, para reduzir o tempo de coagulação em um paciente, para intensificar a hemostasia em um paciente, para reduzir o número de administrações da proteìna do fator de coagulação necessário para deter a hemorragia e manter a hemostasia em um paciente, para reduzir a quantidade de proteìna do fator de coagulação administrada necessária para deter a hemorragia e manter a hemostasia de um paciente, para prolongar o tempo de lise do coágulo em um paciente, para aumentar a resistência do coágulo em um paciente, e para intensificar a formação de coágulo de fibrina em um paciente
NO963568D0 (no) Farmasöytisk preparat for behandling av blodkoagulasjonssykdommer, fremgangsmåter for fremstilling av dette og dets anvendelse
BR0307508A (pt) Composto, composição farmacêutica, e, métodos de tratamento ou prevenção de dor e inflamação e de tratamento de doença
BR0006088A (pt) Derivados de proteìna c
ES2073425T3 (es) Una nueva glicoproteina de tipo trombomodulina susceptible de ser obtenida a partir de la orina.
IS2819B (is) Viðloðunarsameindir í æðum og mótun á starfsemi@þeirra
SE0102147D0 (sv) New methods
ES2119165T3 (es) Nueva actividad de cofactor anticoagulante.
DE3579847D1 (de) Medikamente welche die freifliessenden eigenschaften von blut verbessern und die verwendung in therapeutika.
ATE211487T1 (de) Dermatansulfatezusammensetzung als antithromotisches mittel
ATE286122T1 (de) Protein c derivate
WO2001036462A3 (en) Protein c derivatives
WO1999058098A8 (en) HUMAN ANTITHROMBIN IIIs AND METHODS RELATED THERETO
BR9708005A (pt) C3 convertase resistente à regulação para baixo
BR0008703A (pt) Utilização da tianeptina para a obtenção de medicamentos destinados ao tratamento das patologias da neurodegenerescência
DE59909356D1 (de) Pharmazeutische präparation, enthaltend einen rezeptor-antagonisten zur behandlung von blutgerinnungsstörungen
DE69836278D1 (de) Allele formen von menschlichem stat3
BR9916858A (pt) ((aminoiminometil)amino)alcanocarboxamidas e asaplicações das mesmas em terapia
DE69113049D1 (de) Varianten des gewebeplasminogenaktivators mit vermindertem abbau.
WO2003106666A3 (en) VARIANTS OF PROTEIN C WITH MODIFIED PROPERTIES

Legal Events

Date Code Title Description
FA10 Dismissal: dismissal - article 33 of industrial property law
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]